IHL have already held a successful Pre-IND meeting with FDA on...

IHL have already held a successful Pre-IND meeting with FDA on IHL-42X. That was announced on 17 May 2022.

The next step is a 116 person BA/BE study and submission of an IND (investigational new drug) application in Q1, 2023.

The BA/BE was part of the feedback from FDA during the Pre-IND process.

The feasibility study has been completed for the blended P2 / P3 trial which will involve up to 30 sites and commence H1, 2023.

I’m not sure how much information you’re looking for so let me know if want more detail.